Thanks Neuro. OT - I see Epix only has enough cash to get through Q1-09, and they're going to 'monetize' Vasovist, or sell/partner it off.
I followed Epix years ago, and remember calculating revenues conservatively of approx $150 mil/yr from Vasovist, with approx half of that going to Epix (if my memory is correct). The numbers being bandied about now seem considerably higher, and with the previous partner now out of the picture, Epix presumably will get the entire revenue stream. I wonder how much Epix could get for Vasovist now that it's approved? Their market cap is approx $60-70 mil, which seems low if Vasovist's revenue potential turns out to be even in the $100-200 mil/yr range. I'll have to get back up to speed on the company.
Vasovist is an excellent agent for lighting up the peripheral vascular system. The coronary indication may not be well suited for MRA due to the motion problem, but for all the peripheral vessels it is ideal. It also has the potential to be a monster breakthrough for breast cancer detection (someday), since it lights up and allows visualization of the small blood vessels leading to the tumor long before the tumor is detectible by a mammogram or palpation.
Epix really got jerked around by the FDA, but at least it's finally approved, better late than never.
News 
Market Data 
Discover 
AI
